KeyBanc raises Lifestance Health stock price target on specialty care growth
KeyBanc has increased its price target for Lifestance Health Group (NASDAQ:LFST) to $15.00 from $13.00, maintaining an Overweight rating. This decision is based on the company's specialty care business, particularly its positioning for treatment-resistant depression therapies, and projected revenue growth of 30% CAGR from 2026-2030. The optimistic outlook follows strong Q2 2026 financial results where LifeStance exceeded expectations and raised its full-year guidance, with another firm, Canaccord, also raising its price target to $15.00.
LifeStance Health Group, Inc. (LFST) Stock Forecasts
Argus has issued a HOLD rating for LifeStance Health Group Inc. (LFST), lowering its target price to $12.00. The report, published on September 30, 2026, provides detailed subratings for the company's industry, management, safety, financial strength, growth, and value, all assessed as Medium.
72% of Gen Z say viral fears affect their desire to leave home
A recent LifeStance Health survey reveals that nearly half of all Americans, and a significant 72% of Gen Z, are inhibited from being themselves in public due to the fear of experiencing an unwanted viral moment on social media. This anxiety leads to reduced self-expression, affects their ability to enjoy the present, and impacts their willingness to leave home or attend events. The survey highlights that these concerns negatively affect Gen Z's mood, self-esteem, sleep, and anxiety weekly, suggesting a growing need for mental health support.
Nearly Half of Americans Say Fear of an Unwanted Viral Moment Keeps Them from Being Themselves in Public, LifeStance Survey Finds
A new survey by LifeStance Health reveals that nearly half of Americans, and especially Gen Z, are experiencing mental health impacts due to the fear of unwanted viral moments on social media. This fear is causing individuals to alter their behavior, avoid social situations, and affects their mood, anxiety, and self-esteem. The findings suggest that therapy could play a role in addressing this modern form of social anxiety.
LifeStance Health Group, Inc. (LFST) Stock forecasts
The article provides a title for "LifeStance Health Group, Inc. (LFST) Stock forecasts" but contains no actual content related to the forecast. Instead, it appears to be an error page or a placeholder from Yahoo Finance, displaying navigation, market data, and legal disclaimers. It indicates that the UK markets are closed and includes various market indices and currency exchange rates.
LifeStance Execs Say Interventional Psychiatry Critical to Company’s Expansion Plans in 2027
LifeStance Health plans to expand its geographic footprint to all major U.S. markets in 2027, driven by targeted M&A and de novos. A key part of this expansion is growing its interventional psychiatry offerings, particularly for treatment-resistant depression, and exploring smaller neuromodulation devices. The company will share more details on its plans during its third-quarter earnings call.
Precision Trading with Lifestance Health Group Inc. (LFST) Risk Zones
Stock Traders Daily provides a detailed analysis of Lifestance Health Group Inc. (LFST), highlighting weak near and mid-term sentiment but a strong long-term outlook. The analysis, generated by AI models, offers three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for various risk profiles. It also presents multi-timeframe signal analysis with specific support and resistance levels.
Precision Trading with Lifestance Health Group Inc. (LFST) Risk Zones
This article provides a precision trading analysis for Lifestance Health Group Inc. (LFST), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a significant 54.0:1 risk-reward setup, targeting a 14.1% gain against 0.3% risk.
Form 4 Lifestance Health Group Inc For: 25 September By Investing.com
This article reports on a Form 4 filing for Lifestance Health Group Inc. on September 25. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article indicates this is a standard financial market update regarding insider transactions for the company.
Form 4 Lifestance Health Group Inc For: 25 September
This article reports on a Form 4 filing for Lifestance Health Group Inc. on September 25. The brief piece indicates that Lifestance Health Group Inc. (LFST) saw a 0.34% increase. No further details about the Form 4 are provided within the article.
Two trusts received share gifts from LifeStance (LFST) CEO David Bourdon, with different trustees named.
LifeStance Health Group, Inc. CEO David Bourdon gifted 150,000 shares of common stock to each of two Grantor Retained Annuity Trusts (GRATs) on September 22, 2026. One trust has an immediate family member as trustee, while Bourdon himself is the trustee of the other. No Rule 10b5-1 plan was reported in connection with these gifts.
LFST: Raised Outlook And Buybacks Strengthen The Earnings Story
Analysts have increased their price target for LifeStance Health Group (LFST) to $14.20, driven by updated assumptions for revenue growth, profit margins, and future P/E ratios. The company reported strong Q2 results with revenue up 26.1% year-on-year, exceeding expectations, and announced a share repurchase agreement, further strengthening its financial outlook. Despite a secondary public offering by existing stockholders, the company's raised EBITDA guidance and share buybacks are viewed positively.
LifeStance Health CTO Sells 42,067 Shares for $541,402
LifeStance Health Group's CTO, Vukasin Paunovich, sold 42,067 shares worth over $541,000 on September 2, 2026. Despite the sale, Paunovich retains 205,379 shares, and the transaction is considered routine given the company's stock price has surged 134.5% over the past year. Analysts suggest this sale does not indicate a negative outlook for the company but rather an insider taking profits.
LifeStance Health Group, Inc. (LFST) Stock Price, News, Quote & History
This article provides a detailed overview of LifeStance Health Group, Inc. (LFST), including its current stock price, recent performance, key financial metrics, and analyst ratings. It highlights the company's services in outpatient mental health, its market capitalization, and its year-to-date and historical stock returns compared to the S&P 500. The information presented aims to give potential investors a comprehensive financial snapshot of LFST.
LIFESTANCE HEALTH GROUP, INC. (LFST) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against LifeStance Health Group, Inc. (LFST)
Bernstein Liebhard LLP has issued a class action alert for investors of LifeStance Health Group, Inc. (LFST), reminding them of the October 11, 2022 deadline to file a lead plaintiff motion in a securities class action lawsuit. The lawsuit alleges that LifeStance's Registration Statement for its June 2021 IPO contained materially false and misleading information regarding decreasing virtual visits, increasing in-person costs, and high physician turnover due to burnout. Since the IPO, LifeStance's stock price has significantly dropped by over 56%.
Lifestance Health Group at 2026 Jefferies conference: growth stays strong By Investing.com
Lifestance Health Group presented at the 2026 Jefferies Healthcare Services and Technology Conference, highlighting strong revenue and profit growth, and significant room for market expansion. The company reported a 26% year-over-year revenue increase and a 94% rise in adjusted EBITDA, raising full-year guidance. Lifestance plans to continue expanding its specialty services, implement a new EHR platform through 2027, and aims for mid-teens revenue growth and adjusted EBITDA margins of 15-20% by 2028.
LifeStance Health Group agrees to repurchase 2.0M shares; 22.25M shares sold by insiders
LifeStance Health Group (LFST) announced an underwriting agreement for an offering of 22.25 million common shares, all sold by existing stockholders. The company simultaneously agreed to repurchase 2 million of these shares from the underwriter at the price paid to selling stockholders, without incurring any underwriter compensation on these repurchased shares. LifeStance Health Group received no proceeds from this offering, which closed on September 11, 2026.
Lifestance Health Group stock hits 52-week high at 13.15 USD By Investing.com
Lifestance Health Group's stock (LFST) recently achieved a 52-week high of $13.15, now trading at $13.16 with a $4.96 billion market capitalization. This marks a 143.26% increase over the past year, reflecting strong investor confidence. The company reported robust Q2 2026 financial results, surpassing analyst expectations and leading Canaccord to raise its price target to $15.00 with a Buy rating.
Lifestance Health Group stock hits 52-week high at 13.15 USD
Lifestance Health Group (LFST) has reached a new 52-week high of $13.15, reflecting a 143.26% increase over the past year and indicating strong investor confidence. Despite appearing slightly overvalued by InvestingPro, the company recently reported robust Q2 2026 financial results, surpassing analyst expectations with increased earnings, revenue, and a raised full-year outlook. Canaccord has also raised its price target to $15.00, maintaining a Buy rating based on the company's strong operational performance and growth prospects in outpatient mental health.
LifeStance prices 22.3 million share secondary offering at $12.35
LifeStance Health Group, Inc. (NASDAQ:LFST) announced the pricing of a secondary public offering of 22.25 million shares of common stock at $12.35 per share by certain stockholders. The company will not receive any proceeds from this offering, but has agreed to repurchase 2 million shares from the underwriter. The offering is expected to close around September 11, 2026.
LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group, a major provider of mental health care, announced the pricing of a secondary public offering of 22,250,000 shares of its common stock at $12.35 per share. The offering is by certain selling stockholders, meaning LifeStance will not receive any proceeds from the sale. However, the company has agreed to repurchase 2,000,000 shares from the underwriter.
Why is Lifestance Health stock sliding today?
Lifestance Health Group stock is down nearly 3.9% in pre-open trading after existing stockholders announced a secondary public offering of 22,250,000 shares. The company itself is not issuing new shares and will not receive proceeds, which is viewed negatively by the market, signaling existing holders are cashing out. A concurrent repurchase of 2,000,000 shares by LifeStance is insufficient to offset the negative sentiment, especially amid a broader market downturn.
LifeStance stockholders plan to sell 22.3 million shares
LifeStance Health Group, Inc. announced that certain stockholders intend to sell 22.25 million shares of common stock through a public offering. LifeStance will not receive any proceeds from this sale but plans to concurrently repurchase 2 million shares from the underwriter. Barclays is managing the offering, which is being conducted under a previously filed shelf registration statement.
LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group, Inc. (Nasdaq: LFST) announced that certain stockholders will offer 22,250,000 shares of the company's common stock in a secondary public offering. LifeStance itself will not sell any shares or receive any proceeds but has authorized a concurrent repurchase of 2,000,000 shares from the underwriter. The offering is being made by means of a prospectus filed with the SEC, with Barclays acting as the underwriter.
LifeStance Health CEO Bourdon David Reports Acquisition of 150,000 Shares at No Cost (NASDAQ: LFST)
LifeStance Health Group CEO Bourdon David acquired 150,000 shares at no cost in a code-J transaction on September 2, 2026. This transaction increased his total reported ownership to 1,248,247 shares. The update provides investors with insight into his equity stake in the company.
Lifestance Health Group stock hits 52-week high at $12.97 By Investing.com
LifeStance Health Group (LFST) stock hit a new 52-week high of $12.97, marking a 129.51% increase over the past year and reflecting strong investor confidence and growth in the healthcare sector. The company recently reported impressive Q2 2026 financial results, exceeding Wall Street expectations with increased revenue, visit volumes, and adjusted EBITDA. Despite appearing slightly overvalued, its PEG ratio of 0.23 suggests attractive value relative to its growth trajectory.
Lifestance Health Group stock hits 52-week high at $12.97
Lifestance Health Group Inc. (LFST) stock hit a new 52-week high of $12.97, currently trading at $13 with a market capitalization of $4.81 billion, reflecting a 129.51% increase over the past year. The company recently reported strong Q2 2026 financial results, surpassing Wall Street expectations with adjusted earnings of $0.06 per share and revenue of $435.35 million, leading to a raised full-year outlook. Despite InvestingPro suggesting the stock is slightly overvalued, its PEG ratio of 0.23 indicates good value relative to its growth.
Lifestance Health Group stock hits 52-week high at $12.97 By Investing.com
Lifestance Health Group Inc. (LFST) stock reached a new 52-week high of $12.97, now trading at $13 with a market cap of $4.81 billion, marking a 129.51% increase over the past year. Despite appearing slightly overvalued, its PEG ratio of 0.23 indicates potential value relative to growth. The company also reported strong Q2 2026 financial results, exceeding Wall Street expectations with significant revenue and adjusted EBITDA growth, and raised its full-year outlook.
LifeStance to Present at Upcoming Investor Conferences
LifeStance Health Group, Inc. announced that its management will present at two upcoming investor conferences in September 2026: the Jefferies Healthcare Services and Technology Conference and the 24th Annual Morgan Stanley Healthcare Conference. The presentations will feature CFO Ryan McGroarty and CEO Dave Bourdon, respectively, and webcasts will be available on the company's Investor Relations website. LifeStance is a leading provider of virtual and in-person outpatient mental healthcare.
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
LifeStance Health Group (LFST) has been identified as a strong momentum stock by Zacks Investment Research, earning a Momentum Style Score of 'A' and a Zacks Rank of #1 (Strong Buy). The article highlights LFST's significant short-term and long-term price performance compared to its industry and the S&P 500, along with positive earnings estimate revisions. Investors looking for a stock with potential near-term growth are advised to consider LFST.
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
Wall Street analysts are forecasting a 31.02% upside for LifeStance Health (LFST), with a mean price target of $10.39. While the consensus price target is a common metric, the article highlights that such targets can often be overly optimistic due to analysts' incentives. However, strong agreement among analysts on upward earnings estimate revisions for LFST, coupled with its Zacks Rank #1 (Strong Buy), suggests a legitimate potential for near-term stock appreciation.
LifeStance Health Foundation Partners with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This renewed collaboration builds on a successful inaugural year where LifeStance contributed over $170,000 to AFSP's initiatives. The partnership emphasizes the critical need for continued research to address the urgent public health crisis of suicide, which claimed 48,824 lives in 2024.
LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This renewed collaboration builds on their inaugural year, where LifeStance teammates and the Foundation contributed over $170,000 to AFSP initiatives. The partnership emphasizes the urgent need for research to improve understanding and prevention of suicide, especially given statistics showing over 48,000 deaths by suicide in 2024.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group Inc. (LFST) stock hit a new 52-week high of $12.85, currently trading at $12.67, with a market capitalization of $4.72 billion. This surge reflects a 131.03% increase over the past year, driven by strong investor confidence and the company's robust Q2 2026 results. The mental health services provider reported a 26% revenue growth, a 94% rise in adjusted EBITDA, and exceeded analyst expectations, leading to raised full-year guidance.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group Inc. (LFST) stock recently hit a 52-week high of $12.85, currently trading at $12.67 with a market capitalization of $4.72 billion. The company has seen a 131.03% increase in its stock over the past year and reported strong Q2 2026 results, surpassing analyst expectations with adjusted earnings of $0.06 per share and revenue of $435.35 million. This performance highlights the company's growth trajectory and operational strength in the mental health services sector.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group (LFST) has reached a new 52-week high of $12.85, reflecting a 131.03% increase over the past year. This milestone follows impressive Q2 2026 results, where the company surpassed Wall Street expectations with doubled adjusted earnings, strong revenue growth, and a significant rise in adjusted EBITDA. The company attributes its success to productivity gains, payer contracting, and specialty services, leading to raised full-year guidance.
Lifestance Health Group stock hits 52-week high at 12.85 USD
Lifestance Health Group (LFST) has reached a new 52-week high of $12.85, reflecting a 131.03% increase over the past year. This milestone follows impressive Q2 2026 results, where the company surpassed Wall Street expectations with doubled adjusted earnings per share and revenue growth of 26%, leading to raised full-year guidance. The strong performance highlights the company's operational strength and investor confidence in the mental health services provider.
LifeStance Reaches Settlement in Data Privacy Lawsuit Involving 1 Million Patients
LifeStance Health has agreed to a $3 million settlement in a class-action lawsuit concerning data privacy. The lawsuit, brought by former patients, alleged that the outpatient mental health provider improperly shared identifiable patient data with Meta and Google using third-party tracking pixels on its website between March 2020 and April 2023. As part of the settlement, LifeStance must cease using such pixels and has stated its commitment to patient privacy and HIPAA compliance, while denying the allegations.
$3.02M LifeStance Health Group website tracking class action settlement
LifeStance Health Group has agreed to a $3.02 million class action settlement to resolve claims that it violated patients' privacy rights by using tracking pixels on its website. These pixels allegedly allowed third parties to collect sensitive patient information without consent, violating HIPAA and the Arizona Consumer Fraud Act. Eligible class members, divided into two subclasses based on their interaction with LifeStance's online booking tool, can receive a cash payment, with claims due by September 29, 2026.
Why LifeStance Health Group (LFST) Is Up 5.5% After Profitable Quarter, Higher Guidance And New Buyback
LifeStance Health Group (LFST) reported a profitable second quarter in 2026, with revenue of US$435.35 million and net income of US$23.61 million, a turnaround from a previous net loss. The company also raised its full-year 2026 revenue guidance to US$1.69 billion to US$1.73 billion and announced a new US$100 million share repurchase program after completing a prior one. This positive news, including the swing to profitability and continued capital returns, contributed to a 5.5% increase in its stock price.
Lifestance Health Q2 Call Highlights Profitable Growth
Lifestance Health Group's Q2 earnings call revealed strong growth and expanding profitability, with revenue jumping 26% year-over-year to $435 million and adjusted EBITDA nearly doubling to $66 million. The company raised its full-year revenue and adjusted EBITDA guidance, driven by increased visits, improved pricing, and disciplined cost management. Despite short-term headwinds from investments in technology and clinician compensation, Lifestance Health is focused on long-term growth through specialty services expansion and strategic acquisitions.
LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Recommendation of "Moderate Buy" from Analysts
Analysts have given LifeStance Health Group (NASDAQ:LFST) a consensus "Moderate Buy" rating, with an average 12-month price target of $12.13. The company recently surpassed quarterly earnings expectations, reporting an EPS of $0.06 against an estimated $0.03 and revenues of $435.35 million, a 26.1% year-over-year increase. Despite strong institutional ownership (85.5%), insiders have sold approximately $155 million worth of stock in the past 90 days.
LifeStance Health Group (NASDAQ:LFST) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded LifeStance Health Group (NASDAQ:LFST) from "buy" to "strong-buy" after the company exceeded Q2 earnings and revenue expectations. Despite this upgrade and a "Moderate Buy" consensus from other analysts, insiders have recently sold a significant amount of shares. The stock opened near its 52-week high, reflecting investor interest following strong financial performance.
LifeStance Health director Teresa DeLuca sells $249,993 in shares By Investing.com
LifeStance Health Group director Teresa DeLuca sold 20,441 shares of the company's common stock for $249,993 on August 13, 2026, with the shares trading near their 52-week high after a significant gain. Despite this sale, management has been actively buying back shares, though InvestingPro's Fair Value analysis suggests the stock is slightly overvalued. The company recently exceeded Q2 2026 earnings expectations, reporting strong revenue growth and increased adjusted EBITDA.
LifeStance Health Surpasses Q2 Earnings Expectations Driven by Clinician Growth
LifeStance Health significantly exceeded Q2 earnings expectations, reporting $435.4 million in revenue and an adjusted EPS of $0.11, driven by a 26.1% year-over-year growth and improved operational efficiency. The company raised its full-year guidance for both revenue and EBITDA, reflecting strong management confidence. This success is largely attributed to its expanding clinician base, now over 8,500, and the effective adoption of digital workflow tools in the rapidly growing mental health market.
LifeStance Health Group (NASDAQ:LFST) Given New $13.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for LifeStance Health Group (NASDAQ:LFST) to $13.00 from $9.00, while maintaining a "neutral" rating. This new target implies a potential upside of 2.48% from the stock's previous close. The company recently reported strong quarterly earnings, with $0.06 EPS against an expected $0.03, and revenue of $435.35 million, marking a 26.1% year-over-year increase, despite significant insider stock sales totaling approximately $155 million over the past three months.
LifeStance Health Group, Inc. SEC Filing (Aug 13, 2026)
This article reports on a Form 144 SEC filing by LifeStance Health Group, Inc. (LFST) on August 13, 2026. The filing indicates a proposed sale of 20,441 shares of common stock with an aggregate market value of $249,993.43 by an unnamed person through Fidelity Brokerage Services LLC, originating from restricted stock vesting on June 1, 2025. The document details the filer and issuer information required by the SEC.
5 Insightful Analyst Questions From LifeStance Health Group’s Q2 Earnings Call
LifeStance Health Group (LFST) exceeded Q2 earnings expectations with strong clinician productivity and specialty service expansion, prompting a raised full-year guidance. Analysts questioned management on productivity gains, revenue per visit drivers, EHR rollout, M&A strategy, and sequential EBITDA guidance, receiving insights into the company's operational improvements and future growth plans. Upcoming quarters will focus on specialty service rollout, EHR execution, and continued clinician recruitment.
LifeStance Health Group (NASDAQ:LFST) Major Shareholder Tpg Gp A, Llc Sells 13,643,207 Shares
Major shareholder Tpg Gp A, Llc sold over 13.6 million shares of LifeStance Health Group (NASDAQ:LFST) for approximately $144.9 million, reducing their stake by 12.21%. This transaction follows LifeStance's strong quarterly performance, which saw an EPS beat and 26.1% year-over-year revenue growth, pushing the stock near its 52-week high with a "Moderate Buy" consensus rating from analysts. Despite a COO share sale, the company exhibits positive sentiment from analyst upgrades and a new 52-week high.
Lisa Miller Sells 47,912 Shares of LifeStance Health Group (NASDAQ:LFST) Stock
Lisa Miller, COO of LifeStance Health Group (NASDAQ:LFST), sold 47,912 shares of the company's stock for approximately $519,845, reducing her stake by 14.55%. This transaction followed a strong quarterly earnings report where the company beat EPS estimates and saw a 26.1% increase in revenue, leading to a 6.3% rise in stock price. Analysts maintain a "Moderate Buy" consensus for LFST.
